SCHEMBL3285188

SCHEMBL3285188

Cc1ccc(C[CH]C(=O)N2CCC(N3CCN(C(N)=O)CC3)CC2)cc1C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 3/20 0.41
GAA P10253 1/20 0.40
ALOX12 P18054 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 3/20 0.39
L3MBTL3 Q96JM7 5/20 0.38
L3MBTL1 Q9Y468 5/20 0.38
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
KMT2A Q03164 1/20 0.37
HPGD P15428 2/20 0.36
TP53 P04637 1/20 0.36
CCR3 P51677 2/20 0.35
AXL P30530 1/20 0.35
MERTK Q12866 1/20 0.35
CHRM2 P08172 1/20 0.35
MBTD1 Q05BQ5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3284870 1.00 CCR5 (0.41) CCR5GAAALOX12SMN1; SMN2ALDH1A1
SCHEMBL4717841 0.90 CCR5 (0.39) CCR5GAAALOX12SMN1; SMN2ALDH1A1
SCHEMBL3314680 0.90 CCR3 (0.41) CCR5GAAALOX12SMN1; SMN2ALDH1A1
SCHEMBL4722465 0.90 CCR3 (0.41) CCR5GAAALOX12SMN1; SMN2ALDH1A1
SCHEMBL4718312 0.90 CCR5 (0.39) CCR5GAAALOX12SMN1; SMN2ALDH1A1
SCHEMBL3278543 0.90 GAA (0.41) CCR5GAAALOX12SMN1; SMN2L3MBTL3
SCHEMBL6222355 0.89 L3MBTL3 (0.43) CCR5GAAALOX12SMN1; SMN2ALDH1A1
SCHEMBL3279457 0.89 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1HPGDTP53
SCHEMBL3279563 0.86 ACACB (0.38) CCR5GAAALOX12SMN1; SMN2ALDH1A1
SCHEMBL5250106 0.86 ACACB (0.38) CCR5GAAALOX12SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152171-A1 CGRP Antagonists BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-06-17 US disclosed
US-7700589-B2 CGRP antagonists BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2010-04-20 US disclosed
US-20070244099-A1 CGRP Antagonists RUDOLF KLAUS 2007-10-18 US disclosed
EP-1558601-A1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-08-03 EP disclosed
US-20040132716-A1 CGRP antagonists BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-07-08 US disclosed
WO-2004037811-A1 SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244099-A1 CGRP Antagonists CALCRL, OPRL1, CALCA CCR5 556/4885GAA 4211/4885ALOX12 2473/4885
US-20100152171-A1 CGRP Antagonists CALCRL, OPRL1, CALCA CCR5 556/4885GAA 4211/4885ALOX12 2473/4885
US-20040132716-A1 CGRP antagonists OPRL1, HTR1D, CALCA CCR5 700/4885GAA 4270/4885ALOX12 1859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.